WoodTrust Financial Corp Has $1.43 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

WoodTrust Financial Corp raised its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 93.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,900 shares of the medical device company's stock after acquiring an additional 10,090 shares during the quarter. WoodTrust Financial Corp's holdings in DexCom were worth $1,427,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of DXCM. Private Trust Co. NA boosted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new stake in DexCom during the fourth quarter valued at $33,000. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC boosted its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in DexCom during the fourth quarter valued at $38,000. Institutional investors own 97.75% of the company's stock.

DexCom Trading Down 0.2%

DXCM opened at $79.84 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19. The firm has a market capitalization of $31.31 billion, a PE ratio of 59.58, a P/E/G ratio of 1.71 and a beta of 1.46. The company's 50-day moving average is $80.33 and its 200 day moving average is $79.41.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $0.32 EPS. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, Director Nicholas Augustinos sold 2,618 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $81.69, for a total transaction of $213,864.42. Following the completion of the sale, the director now owns 37,083 shares in the company, valued at $3,029,310.27. This trade represents a 6.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the sale, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 25,724 shares of company stock worth $2,157,034. Insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DXCM shares. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a research report on Saturday. Truist Financial started coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Barclays increased their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.